7 active not recruiting, 1 withdrawn. 8 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Active not recruiting 7, Withdrawn 1 |
| Phase 1 | 2 | Active not recruiting 2 |
Follow LOXO-292: new trials by email Literature Review of LOXO-292 trials Research Report on LOXO-292
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer Carboplatin, Pemetrexed, Selpercatinib - Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Withdrawn | SWOG Cancer Research Network | 2022-07-25 | 2024-07-09 | |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-10-09 |
| Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib - Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2021-02-26 | 2026-05-20 |
| Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial) Selpercatinib - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Active not recruiting | SWOG Cancer Research Network | 124 | 2020-04-08 | 2026-03-23 |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation Selpercatinib - Solid Tumor, Medullary Thyroid Cancer | Phase 2 | Active not recruiting | Eli Lilly and Company | 77 | 2020-03-16 | 2026-08-07 |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Selpercatinib - Medullary Thyroid Cancer, Infantile Myofibromatosis | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 36 | 2019-06-13 | 2026-01-06 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-07-24 |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) LOXO-292 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 857 | 2017-05-02 | 2026-04-16 |
Carcinoma, Non-Small-Cell Lung (5) · Carcinoma, Medullary (4) · Lung Neoplasms (4) · Thyroid Neoplasms (4) · Central Nervous System Neoplasms (3) · Sarcoma (3) · Thyroid Cancer, Papillary (3) · Breast Neoplasms (2) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Colonic Neoplasms (2) · Endocrine Gland Neoplasms (2) · Endocrine System Diseases (2) · Ependymoma (2) · Glioma (2)
Eli Lilly and Company (3) · National Cancer Institute (NCI) (2) · SWOG Cancer Research Network (2) · M.D. Anderson Cancer Center (1)
United States (7) · Australia (4) · Canada (3) · Denmark (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · Puerto Rico (2) · South Korea (2) · Spain (2) · United Kingdom (2) · China (1) · Hong Kong (1) · Israel (1)
Yasir Y Elamin (2) · Andrea T Franson (1) · Donald W Parsons (1) · Mark Zafereo (1)
PMID 32846060, PMID 32846061, PMID 33591402, PMID 34088726, PMID 35353553, PMID 35923928, PMID 35930972, PMID 36062046, PMID 36108661, PMID 36122315, PMID 36657661, PMID 37265412, PMID 37315261, PMID 37655205, PMID 37934000, PMID 38661071, PMID 39085487, PMID 39094065, PMID 39471424, PMID 39759832, PMID 39983053, PMID 41166674, PMID 42686334, PMID 42867148, PMID 42874021
U10CA180886 (2), U10CA180888 (2), 2017 (1), 2019 (1), 2023 (1)